Bardoxolone Methyl as a Potential Therapy for Chemotherapy-Induced Neuropathic Pain: Decreasing Inflammatory Mediators and Restoring Mitochondrial Function.

https://pubmed.ncbi.nlm.nih.gov/38112490

Bardoxolone methyl, an Nrf2 activator, shows potential as a therapeutic strategy for chemotherapy-induced neuropathic pain by decreasing inflammatory mediators and restoring mitochondrial function in the dorsal root ganglia.